AmericaExperts suggest that Covid-19 vaccine should be given to people who are cured and those with long-term symptoms, although the effectiveness of the vaccine has not been studied.
Public health officials hope to vaccinate as many people as possible, even those who have survived Covid-19, to turn the tide of the Covid-19 pandemic, once the vaccine is ready.
While it is not fully understood how the human immune system from Covid-19 responds to the vaccine – especially in people with symptoms lasting weeks and months after diagnosis – it is still possible. have little risk of getting vaccinated.
“The general recommendation is to get vaccinated even if you have a medical problem,” said Dr. David Thomas, professor of medicine and director of the Department of Infectious Diseases at Johns Hopkins University School of Medicine. The answer, but what we know now is the right time to get the vaccine. “
Reinfection with nCoV is rare, but if the levels of natural antibodies decline over time, a person can become infected many times. Doctors and infectious disease specialists agree that people should be vaccinated, even if they have natural immunity.
Vaccines can boost immunity in people who are cured. That is the precautionary measure. Healthy adults over 50 years of age are still advised to get the shingles vaccine even if they had had chickenpox or shingles.
Dr Thomas said: “I got the shot because I wanted more immunity to protect myself from the shingles recurrence. Although I already have the disease and have a certain amount of immunity, I still choose to get the vaccine to double the risk and be more secure “.
Vaccine trials were conducted by Pfizer and Moderna on volunteers of diverse racial and ethnic backgrounds, but did not focus on people who had Covid-19. Those details are part of the vaccine approval process. Thomas said Pfizer and Moderna would have to provide data on the issues that remained even after the FDA approved emergency use. Some of the requirements may include specific questions about the use of the vaccine for people already with Covid-19, as well as all accompanying safety data.
To date, there is no evidence that vaccines will not be safe in people from Covid-19, but more research is needed, says Dr. Sarah Fortune, Head of Immunology and Infectious Diseases at the School of Medicine. Public Health Harvard TH Chan.
She said: “There have been no serious adverse events that make me think this will be a major problem, but I think the analysis needs to be completed. The first question is about safety, the second is yes. Any additional benefits? “
Although the Pfizer and Moderna vaccine trials do not employ symptomatic or infected volunteers, up to 10% of participants tested with nCoV infection, according to Dr. Moncef Slaoui, Principal Advisor of the Rapid Campaign. . These individuals either have no symptoms or have symptoms that are mild enough to go undetected.
“What we do know is that vaccines are safe in this group,” said Slaoui. He also added that more data is needed on how the vaccine works in people who already have symptoms and have Covid-19.
Another big unknown is how will people with persistent Covid-19 symptoms react, says Michael Betts, an immunologist and professor of microbiology at the University of Pennsylvania’s Perelman School of Medicine? It is not clear how many people suffer from Covid-19’s long-term symptoms, but research by the US Centers for Disease Control (CDC) released in July found that 35% of adults have symptoms but not severe enough. hospitalized, but did not return to normal within three weeks of diagnosis.
Part of the challenge in assessing how those patients have been affected by vaccines, is it is unclear why their symptoms persist.
“We really don’t understand these people have to suffer like that, so my concern comes from not knowing the reason for the lingering symptoms,” said Professor Betts.
Dr Thomas said that without knowing the reason for the lingering symptoms in certain patients, it is difficult to know whether the immune response from the vaccine will be beneficial or detrimental.
Professor Betts says people with persistent symptoms need to be assessed individually so that doctors weigh the risks and benefits. The patient also needs to be closely monitored and evaluated over time.
“This could be a very special group with individual evaluations,” he said. “We do not understand symptom prolongation well, so it is difficult to try to predict how the vaccine works,” he said.
Chile (According to the NBC News)